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ABSTRACT:Rheumatoid arthritis is an inflammatory condition characterizedbyoverzealous inflammation that leads
to joint damage and is associated with an increased incidence of cardiovascular disease. Statins are frontline
therapeutics for patients with cardiovascular disease and exert beneficial actions in rheumatoid arthritis. The
mechanism that mediates the beneficial actions of statins in rheumatoid arthritis remains of interest. In the present
study, we found that the administration of 2 clinically relevant statins—atorvastatin (0.2 mg/kg) or pravastatin
(0.2 mg/kg)—to mice during inflammatory arthritis up-regulated systemic and tissue amounts of a novel family
of proresolving mediators, termed 13-series resolvins (RvTs), and significantly reduced joint disease. Of note,
administration of simvastatin (0.2 mg/kg) did not significantly up-regulate RvTs or reduce joint inflammation. We
also found that atorvastatin and pravastatin each reduced systemic leukocyte activation, including platelet-
monocyteaggregates (∼25–60%).These statinsdecreasedneutrophil trafficking to the joint aswell as jointmonocyte
andmacrophagenumbers.Atorvastatin andpravastatinproducedsignificant reductions (∼30–50%) inexpressionof
CD11b and major histocompatibility complex class II on both monocytes and monocyte-derived macrophages in
joints. Administration of an inhibitor to cyclooxygenase-2, the initiating enzyme in the RvT pathway, reversed the
protective actions of these statins on both joint and systemic inflammation. Together, these findings provide
evidence for the role of RvTs in mediating the protective actions of atorvastatin and pravastatin in reducing local
and vascular inflammation, and suggest that RvTs may be useful in measuring the anti-inflammatory actions
of statins.—Walker, M. E., Souza, P. R., Colas, R. A., Dalli, J. 13-Series resolvins mediate the leukocyte-platelet
actions of atorvastatin and pravastatin in inflammatory arthritis. FASEB J. 31, 3636–3648 (2017). www.fasebj.org
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Cardiovascular disease (CVD) is the primary cause of
global mortality, representing ;30% of all deaths (World
Health Organization 2012; http://www.who.int/mediacentre/
factsheets/fs317/en/). In arthritides, cardiovascular compli-
cations are thought to arise from the chronic inflammatory
state that characterizes these conditions and causes .50%
of premature deaths in patients with arthritis (1, 2). Despite
the high incidence of CVD, for many years research into
mechanisms that are engaged by therapeutics in rheuma-
toid arthritis focused on joint protection, with limited evi-
dence on their potential cardiovascular actions. Statins are a
group of molecules that regulate circulating cholesterol
levels by inhibiting the activity of 3-hydroxy-3-methyl-
glutaryl-coenzyme A (HMGCA) reductase. These drugs
are now widely used in the treatment of CVD as a result
of the above effects and because of their limited adverse
effects, and in 2005, their sales in the United States was
estimated to be $19.7 billion (3). Recent evidence suggests
that statins may also be useful in treating a number of
inflammatory diseases, including rheumatoid arthritis,
where atorvastatin (4–6), pravastatin (7), and simvastatin
(8–11) are suggested to exert joint protective actions. It is
now apparent that the protective actions of statins, at least
inpart, are independent of their ability to regulateHMGCA
reductase activity (12); therefore, during the last few years,
there has been significant interest in identifying the mech-
anisms that are responsible for these beneficial actions.
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We recently found that, during bacterial infections,
atorvastatin up-regulates the biosynthesis of a novel
family of lipid mediators, termed 13-series resolvins
(RvTs). This family is composed of 4 molecules, namely
RvT1, RvT2, RvT3, and RvT4 (13). Here, atorvastatin via
nitrosylation of endothelial cyclooxygenase-2 (COX-2)
up-regulates the formation of 13R-HDPA (13R-hydroxy-
7Z,10Z,13R,14E,16Z,19Z-docosapentaenoic acid), a key
intermediate in the biosynthesis of RvT that is then do-
nated to neutrophils where it is converted to bioactive
molecules (13, 14). These mediators form part of a novel
genus of endogenous host protective molecules, termed
specialized proresolving mediators, that fine-tune the
inflammatory response to promote its termination (12,
15–18). In ongoing infections, RvT down-regulates the
formation of proinflammatory mediators, including ei-
cosanoids and the pyroptotic cytokine IL-1b, as well as
regulates leukocyte trafficking and bacterial clearance that
promotes the resolution of infectious inflammation (13).
Given the potent actions exerted by RvT in the regula-
tion of host responses and that atorvastatin promotes their
formation during infectious inflammation, we questioned
whether the joint protective actions of atorvastatin in in-
flammatory arthritis were mediated by these molecules.
We then investigated whether atorvastatin dampened
systemic inflammation in experimental arthritis by
assessing its ability to regulate circulating leukocyte re-
sponses and the role of RvTs in mediating these actions.
Wealso testedwhether regulationofRvTwas sharedwith
pravastatin and simvastatin. Here, we found that ator-
vastatin and pravastatin differentially regulated RvT
formation in plasma and joints of mice during experi-
mental arthritis. Each of these statins also reduced joint
and systemic leukocyte activation, systemic platelet acti-
vation, and joint disease. Of note, inhibition of RvT bio-
synthesis reversed both the local and systemic protective
actions exerted by atorvastatin and pravastatin.
MATERIALS AND METHODS
Materials
Materials included liquid chromatography–grade water, meth-
anol and acetic acid (Thermo Fisher Scientific, Waltham, MA,
USA), Eclipse C18 Poroshell column (2.8 mm 3 4.6 mm 3
150 mm; Agilent Technologies, Santa Clara, CA, USA), and C18
solid-phase extraction columns (Biotage, Uppsala, Sweden);
synthetic and authentic standards for liquid chromatography–
tandem mass spectrometry quantitation and deuterium (d) in-
ternal standards (d5-RvD2, d5-lipoxinA4 (LXA4), d4-prostaglandin
(PG) E2 and d4-leukotriene (LT) B4), which were purchased from
CambridgeBioscience (Cambridge,UnitedKingdom)orprovided
by Charles N. Serhan (Harvard Medical School, Boston, MA,
USA); atorvastatin, pravastatin sodium salt, simvastatin sodium
salt, andcelecoxib (CambridgeBioscience);Dulbecco’sPBS (DPBS;
with and without calcium and magnesium), RPMI-1640, collage-
nase D, DNAseI, paraformaldehyde, Histopaque-1077, trisodium
citrate, HBSS, penicillin-streptomycin, and dextran from Leuco-
nostoc spp. (Mr 450,000–650,000), IL-1b, and TNF-a (Sigma-
Aldrich, St. Louis, MO, USA); fetal bovine serum, CD11b-PE-
Texas Red, CD62P-Brilliant Violet 650, and CountBright Absolute
Counting Beads (Thermo Fisher Scientific); whole blood lysing
reagentskit (BeckmanCoulter,Brea,CA,USA); collagenase type II
(Worthington Biochemical, Lakewood, NJ, USA); and anti-mouse
IgG, CD64-PE, Ly6G-Alexa Fluor 700, Ly6C-Brilliant Violet 785,
CD45-APC/Cy7, IA/IE-Brilliant Violet 650, CD11b-Alexa Fluor
488, Siglec F-APC, CD115-Brilliant Violet 711, CD43-Brilliant
Violet 510, Ly6C-Alexa Fluor 488, CD11c-Brilliant Violet 785,
CD115-Brilliant Violet 711, CD43-Alexa Fluor 647, and CD41-
Brilliant Violet 510 (BioLegend, San Diego, CA, USA).
Animals
MaleC57BL/6mice (11wkold)wereprocured fromCharlesRiver
Laboratories (Kent, United Kingdom). Experiments strictly ad-
hered to United KingdomHomeOffice regulations (Guidance on
the Operation of Animals, Scientific Procedures Act) and Labo-
ratoryAnimal ScienceAssociationGuidelines (GuidingPrinciples
onGood Practice for AnimalWelfare and Ethical Review Bodies).
All animals were provided with standard laboratory diet and
water ad libitum and kept on a 12-h light/dark cycle.
Inflammatory arthritis
Male C57BL/6 mice (11 wk old) were administered K/BxN se-
rum (100 ml, i.p.) on d 0 and 2 to initiate inflammatory arthritis
(19). Mice were then given atorvastatin, pravastatin, simvastatin
(0.2 mg/kg each), or vehicle (DPBS2/2 that contained 0.05%
ethanol) via i.v. injection on d 3, 5, and 7. Clinical scores were
monitored daily by using a 26-point arthritic scoring system.
Swelling and redness of mouse ankles/wrists, pads, and digits
were inspected daily as previously described (19). Blood and
paws were collected at the indicated time intervals.
In select experiments,miceweregiven10mg/kgcelecoxib 1h
before statin injections. Blood and paws were collected either
on d 8 after arthritis onset or 2 h after statin injection on d 7.
Flow cytometry
Whole blood was collected by using heparin-lined syringes via
cardiac puncture. Cellswere incubatedwith Fc-blocking IgGand
fluorescent-labeled Abs (see Supplemental Methods for Ab de-
tails) for 45 min on ice. Cells were washed and incubated with
0.1% live/dead stain for 30min on ice. Redblood cellswere lysed
and fixed using thewhole blood lysing reagent Kit. Stainingwas
then evaluated by using LSRFortessa cell analyzer (BD Biosci-
ences, SanDiego, CA,USA) and analyzedusing FlowJo software
(v.10; Tree Star, Ashland, OR, USA).
Paws were harvested and leukocytes were isolated as pre-
viously described (19). In brief, paws were incubated in RPMI-
1640 that contained 0.5 mg/ml collagenase D and 40 mg/ml
DNaseI at 37°C for 30 min with vigorous agitation. Isolated cells
were passed through a 70-mM strainer and suspended in RPMI-
1640 that contained 2 U/ml penicillin, 100mg/ml streptomycin,
and 10% fetal bovine serum, then centrifugated at 400 g for
10min. Isolated cellswere suspended inDPBS2/2 that contained
0.02% bovine serum albumin and 1% Fc-blocking IgG (v/v) and
were incubatedwith 0.1% live/dead stain for 20min on ice. Cells
were washed using DPBS2/2 and incubated with fluorescent-
labeledAbs (seeSupplementalMethods forAbdetails) for 45min
on ice. These were then washed and fixed using 1% para-
formaldehyde.CountBrightAbsoluteCountingBeadswereused
for leukocyte enumeration. Staining was evaluated using
LSRFortessa cell analyzer and analyzed using FlowJo software.
Human neutrophil–endothelial cell incubations
Umbilical cords were collected by the midwifery staff of the
Maternity Unit, Royal London Hospital (protocol approved by
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East London and The City Health Authority Research Ethics
Committee; 06/Q0605/40), and HUVECs were isolated as pre-
viously described (20). Cells were then incubated with IL-1b
and TNF-a (10 ng/ml each, 16 h, 37°C, 5% CO2).
Neutrophils were isolated from the blood of healthy con-
senting donors in accordance with the Declaration of Helsinki
and Queen Mary Research Ethics Committee (QMREC)–
approved protocol (QMREC 2014:61). Blood was collected by
using 3.2% sodium citrate as an anticoagulant and centrifuged
(100 g for 20 min). Platelet-rich plasma was removed as pre-
viously described (13). Red blood cells were agglutinated by
addingDPBS2/2 and 6%dextran, gentlymixing and incubating
at room temperature for 20 min. The resulting supernatant was
layered over Histopaque-1077 and centrifuged (350 g for
30 mins). Red blood cells in the resulting pellet were lysed by
using ice-coldwaterand transferring toHBSS.Cellswereobtained
via centrifugation at 250 g for 10 min.
Incubations were conducted as previously described (13). In
brief, HUVECs (8.53 105 cells/cm2) were incubated with IL-1b
(10 ng/ml) and TNF-a (10 ng/ml) for 16 h, then with atorvas-
tatin, pravastatin, or vehicle (DPBS that contained 0.05%ethanol)
for 30 min at 37°C. Four million neutrophils were added to each
well and cellswere incubated for60min (37°C). Incubationswere
quenched with ice-cold methanol that contained deuterated in-
ternal standards and samples were taken for lipid mediator
profiling.
Lipid mediator profiling
Ice-cold methanol that contained 500 pg of each deuterated (d)
internal standard—d8-5S- hydroxyeicosatetraenoic, d4-LT B4, d5-
LXA4, d4-PGE2, and d5-RvD2—was added to samples. These
represent the various chromatographic regions of identified lipid
mediators to allow quantification and assessment of sample re-
covery. Lipidmediatorswere extractedandprofiling conductedas
previously described (13, 21, 22). In brief, lipid mediators were
extracted by using solid-phase extraction techniques and Extra-
Hera (Biotage) carried out as previously described (22). Lipid
mediators were identified and quantified by using liquid
chromatography–tandem mass spectrometry–based lipid media-
tor profiling. Multiple reaction monitoring was carried out by us-
ing signature Q1 (parent ion) and Q3 (characteristic daughter ion)
ion pairs for each molecule, which were acquired in negative ion-
izationmode. Lipidmediators were identified in accordance with
published criteriamatching retention time andwith aminimumof
6 diagnostic ions in the tandemmass spectrometry spectra (22).
Histology
Paws were placed in 10% formaldehyde (v/v; in water that
contained 0.65% Na2HPO4 and 0.4% NaH2PO4) for 48 h. These
were then placed in 10% EDTA in DPBS for 2 wk. When decal-
cified, pawswere embedded inwax as previously described (19).
Four-micron sections were obtained and hematoxylin and eosin
staining was carried out by the Barts Cancer Institute Pathology
Core as previously described (19).
Statistics
Results are presented as means 6 SEM. Differences between
groups were tested by using GraphPad Prism 7 (GraphPad
Software, La Jolla, CA, USA) and 1-way ANOVA with post hoc
Dunnett’s, Sidak’s, or Tukey’s multiple comparisons test. Where
appropriate, 1-sampleStudent’s t test comparedwithnormalized
vehicle or 2-way ANOVAwere used. The criterion for statistical
significance was P, 0.05.
RESULTS
Differential regulation of local and systemic
RvT by atorvastatin, pravastatin, and
simvastatin during inflammatory arthritis
We first investigated whether atorvastatin regulated
RvT formationduring inflammatory arthritis andwhether
this action was unique to this statin or shared with other
clinically relevant statins, namely pravastatin and sim-
vastatin (7–11). To test this, we administered arthritogenic
serum fromK/BxNmice on d 0 and 2. This serum leads to
anFcg-mediated immune responsewith a rapid onset and
severe inflammatory arthritis (23). Mice were then admin-
istered atorvastatin (0.2 mg/kg), pravastatin (0.2 mg/kg),
simvastatin (0.2 mg/kg), or vehicle in a therapeutic
paradigmond 3, 5, and 7 post–serumadministration, at
a timewhen clinical signs of diseasewere observed (Fig.
1A). Plasma and paws were collected 24 h after the last
statin dose, and lipid mediators were identified and
quantifiedbyusing liquidchromatography–tandemmass
spectrometry–based lipid mediator profiling. In paws
from arthritic mice, we identified mediators from all 4
major bioactivemetabolomes, includingD-series resolvins
and RvTs (Fig. 1B, C). These mediators were identified in
accordance with published criteria, including matching
retention times toauthenticor synthetic standards (Fig. 1B)
and at least 6 ions in the MS-MS (Fig. 1C) (21). Using
multiple reaction monitoring, we determined the concen-
trations of mediators that were identified in these paws.
Here, we found that in joints from mice that received
atorvastatin there was a 43% increase in overall RvT
amounts as a result of increased RvT1, RvT2, RvT3, and
RvT4 comparedwithpaws fromvehicle-treatedmice (Fig.
1D and Supplemental Table 1).Of note, the concentrations
of these mediators were within their described bioactive
ranges (13). Pravastatin also increased pawRvT by;20%,
with increases in joint RvT1 and RvT2 concentrations,
whereas simvastatin did not significantly increase joint
RvT concentrations (Fig. 1D and Supplemental Table 1).
Assessment of plasma mediator levels demonstrated
decreases in LT B4, PGD2, PGE2, PGF2a, and thromboxane
B2 in mice that were administered either pravastatin or
atorvastatin (Supplemental Table 2). In thesemice,we also
found an increase in plasma levels of RvT concentrations,
with RvT1 being increased by both atorvastatin and
pravastatin, whereas RvT4 was only increased by ator-
vastatin (Supplemental Table 2).
Given that statins are rapidly cleared from circulation
with a half-life of;14 h (24) and;3 h (25) for atorvastatin
and pravastatin, respectively, we next investigated
whether systemic regulation of RvT biosynthesis by these
statins was more pronounced immediately after dosing.
For this purpose, arthritis was initiated by using K/BxN
serum and mice were administered atorvastatin and
pravastatin as previously described. Blood was then col-
lected 2 h after the last statin dose on d 7 and lipid medi-
ators were identified and quantified by using lipid
mediator profiling. In plasma from mice that were given
atorvastatin, we found a significant increase (.200%) in
RvTs, with increases in RvT1, RvT2, and RvT3 compared
3638 Vol. 31 August 2017 WALKER ET AL.The FASEB Journal x www.fasebj.org
 Vol.31,  No.8 , pp:3636-3648, August, 2017The FASEB Journal. 161.23.96.77 to IP www.fasebj.orgDownloaded from 
Figure 1. Increased RvTs in paws from mice that were administered atorvastatin and pravastatin during inflammatory arthritis. A)
Arthritogenic K/BxN serum (100 ml, i.p.) was administered to mice to initiate disease, and disease progression was monitored
daily using clinical scores. Arrows denote days when mice were given statins or vehicle (see Materials and Methods for details).
B–D) Doses of 0.2 mg/kg atorvastatin, pravastatin, simvastatin, or vehicle (DPBS that contained 0.05% ethanol) were
(continued on next page)
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with vehicle-treated mice (Supplemental Fig. 1 and Sup-
plemental Table 3). In thesemice,we also founddecreased
circulating amounts of inflammation-initiating eicosa-
noids, including PGD2 and PGE2. Assessment of plasma
lipid mediator profiles from mice that were administered
pravastatin alsodemonstratedamarked increase (.100%)
in peripheral blood RvTs, with RvT1 demonstrating the
greatest increase compared with vehicle-treated mice
(Supplemental Fig. 1 and Supplemental Table 3). In these
mice, we also observed decreases in circulating PGD2
(;46%) and PGE2 (;29%). Together, these results dem-
onstrate that atorvastatin and pravastatin increase both
joint and plasma RvTs and decrease systemic inflamma-
tion during inflammatory arthritis.
Given that in the vasculature, RvT is produced during
neutrophil endothelial interactions (13),we next questioned
whether the increased RvT observed in murine systems by
pravastatin was also translatable to humans. For this, we
incubated human neutrophil–endothelial cell cocultures
with pravastatin and assessed its ability to regulate RvTs.
Here, we found that pravastatin dose-dependently up-
regulated the concentrations of all 4 RvTs to a similar extent
as that observed by atorvastatin (Supplemental Fig. 2).
Atorvastatin and pravastatin reduce joint
inflammation and protect against
leukocyte-mediated tissue damage
We next investigated whether atorvastatin and pravastatin
at doses that increased RvTs also reduced joint inflamma-
tion. Arthritis was initiated and mice were treated and dis-
ease progressionmonitored as described above. Inmice that
wereadministeredvehicle, signsofdiseasewereobservedas
early as d 2, and disease severity reached amaximum at d 6
with a score of 11.9 6 0.9, after which disease activity pla-
teaued to d 7 (Fig. 2A). When mice were administered
atorvastatin, disease progression was dampened as early
as d 4 (1 d after treatment initiation), with disease scores
reaching amaximumscore of 9.161.2 at d 5. This reduction
indiseaseactivitywassustaineduntild7 (Fig. 2A). Similarly,
when mice were administered pravastatin, disease activity
at d 5was found to be lower comparedwithmice thatwere
administered vehicle alone, with a ;23% reduction in dis-
ease activity that was maintained until d 7 (Fig. 2B). Ad-
ministration of simvastatin at doses thatwere equal to those
of atorvastatin and pravastatin did not significantly reduce
disease activity (Fig. 2C). These findings were also reflected
in the extent of paw swelling, where atorvastatin and
pravastatin reduced joint swelling as measured by a de-
crease in midfoot pad thickness (Fig. 2D).
We next assessedwhether atorvastatin, pravastatin, and
simvastatin displayed joint protective actions.Hematoxylin
and eosin–stained sections of knee joints from mice that
were administered atorvastatin and pravastatin demon-
strated reduced leukocyte infiltration, pannus formation,
and joint damage compared with vehicle-treated mice,
whereas these parameterswere unaltered inmice thatwere
administered simvastatin (Fig. 2E). Together, these findings
demonstrate that atorvastatin and pravastatin are more
potent than simvastatin at regulating local inflammation
and protecting from leukocyte-mediated joint damage in
inflammatory arthritis.
Decreased leukocyte activation in joints and
blood from arthritic mice by atorvastatin
and pravastatin
To ascertain whether these statins regulated systemic in-
flammation in inflammatoryarthritis,weassessed the levels
of platelet–leukocyte aggregates in peripheral blood from
arthritic mice, given the relationship of these heterotypic
aggregates and cellular activationwith CVD (26, 27). Using
flow cytometry, we found that atorvastatin regulated the
expression of CD11b on both nonclassic and classic mono-
cytes as well as platelet–monocyte aggregates as measured
by a decrease in CD62P (Fig. 3A, B) and CD41 expression
(n = 9 mice) on these monocyte subsets. Atorvastatin
administration also regulated neutrophil and platelet
responses, significantly reducing neutrophil CD11b ex-
pression, platelet-neutrophil aggregates (Fig. 3C), and de-
creasing platelet CD62P expression by ;60% (Fig. 3D)
compared with mice that were given vehicle alone. Similar
findings were made with peripheral blood leukocytes and
platelets from mice that were administered pravastatin,
where therewasareduction inmonocyteCD11bexpression
(;10% for nonclassic and ;40% for classic monocytes),
platelet leukocyte aggregates (;35% for both monocyte
subsets and;25% for neutrophils), and platelet activation,
with a reduction of ;70% in CD62P expression (Fig. 3).
Simvastatin did not significantly regulate leukocyte CD11b
expression,whereasheterotypicaggregates thatwereformed
by classic monocytes and platelets and platelet CD62P
expressionwere reduced (Fig. 3).These resultsdemonstrate
that atorvastatin and pravastatin regulate systemic inflam-
mation, dampening circulating monocyte, neutrophil, and
platelet activation during inflammatory arthritis.
Wenext testedwhether theseactionsalso translated toa
regulation of leukocyte trafficking and activation in the
joint. We first assessed the trafficking of nonclassic
monocytes to inflamed joints, given their role in disease
onset and propagation of K/BxN serum–initiated in-
flammatory arthritis (28). Flow cytometric analysis of
leukocytes that were isolated from joints of mice given
atorvastatin demonstrated a significant reduction in the
total numbers of nonclassic monocytes recruited to joints
(.60%). There was also a reduction in CD11b and a
administered intravenously on d 3, 5, and 7 after disease onset. Paws were collected on d 8, and lipid mediators were identified
and quantified by using lipid mediator profiling. B) Representative multiple reaction monitoring chromatograms of identified
lipid mediators derived from docosahexaenoic acid, n-3 docosapentaenoic acid, eicosapentaenoic acid, and arachidonic acid. C)
Tandem mass spectrometry spectra employed in the identification of RvT2 and RvT3. D) Percentage regulation of RvT1, RvT2,
RvT3, and RvT4 compared with vehicle (D). Results are means 6 SEM; n = 9 for vehicle, 11 for atorvastatin, 11 for pravastatin, and
9 for simvastatin-treated mice from 4 independent experiments. *P , 0.05 vs. vehicle.
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Figure 2. Atorvastatin and pravastatin reduced disease severity and protected joint architecture. Arthritogenic K/BxN serum
was administered to mice on d 0 and 2. A–C) Disease progression was monitored by using a 26-point clinical score in mice
given atorvastatin (0.2 mg/kg; A), pravastatin (0.2 mg/kg; B), simvastatin (0.2 mg/kg; C), or vehicle (DPBS that contained
0.05% ethanol) on d 3, 5, and 7. Results are means 6 SEM; n = 8 for vehicle, 10 for atorvastatin, 10 for pravastatin, and 6 for
(continued on next page)
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significant reduction in major histocompatibility complex
class II (MHCII) expression on these cells compared with
mice that were administered vehicle alone (Fig. 4A). We
found that neutrophil trafficking was decreased in mice
that received atorvastatin compared to vehicle-treated
mice (Fig. 4B). In these mice, we found that statin admin-
istration down-regulated expression of neutrophil CD11b
and MHCII, although this did not reach statistical signifi-
cance (Fig. 4B). Assessment of macrophage trafficking to
joints also demonstrated a significant reduction in the
number of monocyte-derived macrophages as well as in
the expression of activation markers CD11b and MHCII
(Fig. 4C). Similar findings were also made with mice that
were administered pravastatin with a reduction in joint
monocyte, neutrophil, and macrophage numbers and
activation profile (Fig. 4). Of note, although simvastatin
regulated the expression of some activation markers on
these cell subsets, it did not significantly reduce paw leu-
kocyte numbers compared with mice given vehicle alone
(Fig. 4). Together, these findings demonstrate that prava-
statin and atorvastatin also regulate joint leukocyte traf-
ficking and activation in inflammatory arthritis.
COX-2 inhibition reverses protective actions
of atorvastatin and pravastatin
To assess the contribution of RvTs in the protective ac-
tions exerted by atorvastatin and pravastatin, we next
investigated whether inhibition of COX-2—the initiating
simvastatin-treated mice from 3 independent experiments. D) Maximum percentage increase in midfoot pad thickness. Results
are means 6 SEM; n = 8 for vehicle, 10 for atorvastatin, 10 for pravastatin, and 6 for simvastatin-treated mice from 3 independent
experiments. E) Representative hematoxylin and eosin–stained knee sections of mice collected on d 8 using EVOS FL imaging
system. Original magnification, 34. Results are representative of n = 8 for vehicle, 10 for atorvastatin, 10 for pravastatin, and 6 for
simvastatin-treated mice from 3 independent experiments. Arrows denote leukocyte infiltration. F, femur; IFP, infrapatellar fat
pad; m, meniscus; PF, pannus formation; T, tibia. *P , 0.05 vs. vehicle using 1-way ANOVA with post hoc Dunnett’s multiple
comparisons test; **P , 0.01, ***P , 0.05 vs. vehicle using ordinary 2-way ANOVA.
Figure 3. Differential regulation of circulating leukocyte and platelet activation by each of the statins in inflammatory arthritis.
Serum-induced arthritis was initiated in mice and atorvastatin, pravastatin, simvastatin (0.2 mg/kg each), or vehicle (DPBS that
contained 0.05% ethanol) were administered on d 3, 5, and 7. On d 8, blood was collected. Leukocyte subsets and activation were
identified by using fluorescently labeled Abs and flow cytometry. Activation markers on nonclassic monocytes (A), classic
monocytes (B), neutrophils (C), and platelets (D) were assessed as percentage decrease from vehicle. Results are means 6 SEM;
n = 9 for vehicle, 11 for atorvastatin, 11 for pravastatin, and 9 for simvastatin-treated mice from 4 independent experiments. *P ,
0.05 vs. vehicle using 1-way ANOVA with post hoc Dunnett’s multiple comparisons test.
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enzyme in the RvT pathway (13)—reversed the protective
actions of pravastatin and atorvastatin. Clinical scores of
mice that were administered celecoxib, a COX-2 selective
inhibitor, immediately before atorvastatin were similar to
those of mice that received vehicle alone and higher than
those of mice that received atorvastatin (Fig. 5A). Simi-
larly, celecoxib also blunted the anti-inflammatory actions
of pravastatin as measured by an increase in disease
Figure 4. Reduction of monocyte, neutrophil, and macrophage activation, as well as trafficking to the joint, by atorvastatin and
pravastatin in inflammatory arthritis. Serum-induced arthritis was initiated in mice and atorvastatin, pravastatin, simvastatin
(0.2 mg/kg each), or vehicle (DPBS that contained 0.05% ethanol) were administered on d 3, 5, and 7. Front paws were collected
on d 8 and digested to liberate infiltrating leukocytes. Leukocyte subsets were defined by using Abs against specific markers and
flow cytometry. Trafficking and activation of nonclassic monocytes (A), neutrophils (B), and monocyte-derived macrophages (C)
were assessed. Results are means 6 SEM; n = 9 for vehicle, 11 for atorvastatin, 11 for pravastatin, and 9 for simvastatin-treated mice
from 4 independent experiments. *P , 0.05 vs. vehicle using 1-way ANOVA with post hoc Dunnett’s multiple comparisons test.
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Figure 5. Inhibition of RvT production by celecoxib reverses the joint protective actions of atorvastatin and pravastatin.
Inflammatory arthritis was initiated by using arthritogenic serum (see Materials and Methods for details). A, B) On d 3, 5, and 7,
mice were administered celecoxib (10 mg/kg) or vehicle (DPBS that contained 0.05% ethanol) and after 1 h given atorvastatin
(0.2 mg/kg; A), pravastatin (0.2 mg/kg; B), or vehicle (PBS that contained 0.05% ethanol). Disease activity was assessed daily. C)
(continued on next page)
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activity comparedwithmice that received the statin alone
(Fig. 5B). This loss of the protective actions of pravastatin
andatorvastatin inmice thatweregivencelecoxibwasalso
associatedwith an;60% reduction in joint RvT and RvT1
concentration that was .75% compared with mice that
were given pravastatin or atorvastatin alone (Fig. 5C). In
thesemice, we also found a significant reversal of the joint
protective actions of both statins where there was an in-
crease in pannus formation and loss of joint architecture in
mice that were given celecoxib compared with mice that
were administered each statin alone (Fig. 5D).
We next investigated whether COX-2 inhibition also
reversed the leukocyte-directed actions exerted by ator-
vastatin and pravastatin. Celecoxib administration blun-
ted the protective actions of atorvastatin on circulating
leukocytes and platelets, increasing blood platelet–
monocyte and platelet–neutrophil aggregates as well as
expressionofCD11bonboth leukocyte subsets (Fig. 6A,B).
Celecoxib administration also increased the expression
ofCD62Pon circulatingplatelets comparedwithmice that
received atorvastatin alone (Fig. 6C).
Inhibition of COX-2 reversed the actions of atorvastatin
on leukocyte trafficking and activation in the joint, in-
creasing the numbers of nonclassic monocytes (Fig. 6D),
neutrophils (Fig. 6E), andmonocyte-derivedmacrophages
(Fig. 6F) that are recruited to inflamed joints. Expression of
activationmarkers on these leukocytes was also increased
after celecoxib inhibition compared with mice that were
given atorvastatin alone (Fig. 6D–F). Similar findingswere
alsomadewhenwe assessed systemic and joint leukocyte
responses and trafficking in mice that were administered
celecoxib together with pravastatin. Here, we found that
COX-2 inhibition returned the activation profile of circu-
lating leukocytes and platelets to that observed in mice
receiving vehicle alone (Supplemental Fig. 3A–C). Simi-
larly, leukocyte trafficking and activation in joints was
increased to levels that were similar to those found in
vehicle-treated mice (Supplemental Fig. 3D–F). Together,
these findings demonstrate that inhibition of COX-2 re-
duced RvT production and abolished the joint and sys-
temic protective actions of pravastatin and atorvastatin in
inflammatory arthritis.
DISCUSSION
Findings presented in this manuscript demonstrate that
bothatorvastatinandpravastatin increaseRvTproduction
in inflammatory arthritis. Up-regulation in tissue and
blood concentrations of these specialized proresolving
mediators was associatedwith a reduction in joint disease
activity aswell as joint leukocyte trafficking and activation.
In addition, both atorvastatin and pravastatin decreased
systemic inflammation, reducing platelet, monocyte, and
neutrophil activation.Theprotectiveactionsof these statins
were reversed by COX-2 inhibition. Of note, simvastatin
did not increase RvTs and displayed blunted actions in the
regulation of joint disease and leukocyte responses. To-
gether, these findings establish the rank order potency of
atorvastatin, pravastatin, and simvastatin in regulating
RvTs aswell as the role of thesemolecules inmediating the
protective actions of these statins.
Rheumatoid arthritis is characterized by an unabated
inflammatory response that progressively leads to joint
destruction and, ultimately, can be debilitating (29, 30).
Thispersistent inflammatory response is also thought tobe
an underlying cause for the increased risk of developing
CVD in patients with arthritis (1, 2). In this context, statins
protect fromCVDandrecent studies suggest that theyalso
reduce disease activity in patients with rheumatoid ar-
thritis (4–11). It is evident that the pleiotropic actions
of statins cannot be uniquely ascribed to inhibition of
HMGCA reductase activity. Studies investigating poten-
tialmechanisms thatmaybe engagedby statins found that
atorvastatin (31) and lovastatin (32) up-regulate the for-
mation of 15-epi-LXA4, which mediates their actions in
cardiovascular and mucosal protection, respectively. In
cardiac myocytes atrovastatin promotes 15-epi-LXA4
formation by increasing the phosphorylation of 5-
lipoxygenase (31).
We recently demonstrated that, in the vasculature,
atorvastatin up-regulates the formation of RvTs and that
this pathwaywas responsible formediating the protective
actions of statins in bacterial infections (13). By using lipid
mediator profiling, in the present study we found that
this pathway was also regulated in the context of in-
flammatory arthritis by atorvastatin (Fig. 1 and Supple-
mentalFigs. 1 and2).Wealso found that theRvTpathway,
at least inpart,was responsible for theprotectiveactions of
this statin in controlling various aspects of inflammatory
arthritis, including joint and vascular inflammation (Fig.
5). This regulation of the RvT pathway was shared with
pravastatin that increased both joint and circulating RvT
amounts,which suggests that thesemoleculesmediate the
systemic and local protectiveactions of these 2 statins. This
is further supported by results obtained with both cele-
coxib and simvastatin, given that in either case, failure to
up-regulate RvTs, in particular RvT1,was associatedwith
increaseddisease activity (Figs. 5 and6).Ofnote, inhuman
neutrophil-endothelial cell incubations, simvastatin in-
creasedRvT levels (n=4healthyvolunteers), although this
was to a much lesser extent than atorvastatin and prava-
statin. These results suggest that simvastatin is not as ef-
fective at promoting COX-2 S-nitrosylation as the other 2
statins. Furthermore, joint and plasma 15-epi-LXA4 were
not significantly regulated in these mice, which under-
scores the role of RvTs in mediating the actions of these
statins (Supplemental Tables 1–3).
On d 8, paws were collected, and RvTs were identified and quantified by using liquid chromatography–tandem mass
spectrometry–based lipid mediator profiling. *P , 0.05; **P , 0.01 vs. atorvastatin or pravastatin alone using 1-way ANOVA with
post hoc Sidak’s multiple comparisons test. D) Representative hematoxylin and eosin–stained knee sections of mice collected on
d 8 using EVOS FL imaging system. Original magnification, 34. Results are means 6 SEM; n = 9 for vehicle, 11 for atorvastatin, 11
for pravastatin, 7 for celecoxib plus atorvastatin, and 6 for celecoxib plus pravastatin-treated mice per group from 2–3
independent experiments. *P , 0.05 vs. vehicle using ordinary 2-way ANOVA.
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Leukocytes, includingmonocytes, are implicated in the
propagation of various aspects of CVD (26, 27). Studies
investigating the role of different monocyte subsets in
atherosclerosis, for example, found elevated classic and
nonclassic monocytes in atherosclerotic plaques (33).
Platelets play an important role in monocyte activation
Figure 6. COX-2 inhibition reverses the protective actions of atorvastatin on both systemic and joint leukocytes. Serum-induced
arthritis was initiated on d 3, 5, and 7 and mice were administered celecoxib (10 mg/kg) or vehicle (DPBS that contained 0.05%
ethanol) and, after 1 h, given atorvastatin (0.2 mg/kg) or vehicle (DPBS that contained 0.05% ethanol). Blood was collected on
d 8 and leukocyte subsets and activation were identified by using fluorescently labeled Abs and flow cytometry. A–C) Activation
markers on circulating nonclassic monocytes (A), neutrophils (B), and platelets (C). Results are presented as percentage
decrease from vehicle. D–F) Leukocytes were recovered from the inflamed paws (see Materials and Methods for details) on d 8.
Trafficking and activation profile for nonclassic monocytes (D) neutrophils (E), and monocyte-derived macrophages (F) were
assessed by using flow cytometry. Results are means 6 SEM; n = 9 for vehicle, 11 for atorvastatin, 11 for pravastatin, and 7 for
celecoxib plus atorvastatin-treated mice from 2 independent experiments. *P , 0.05 vs. vehicle, #P , 0.05 vs. atorvastatin using
1-way ANOVA with post hoc Dunnett’s multiple comparisons test.
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and transmigration.Monocyte–platelet aggregates lead to
an enhanced ability of monocytes to interact with the
vascular endothelium and increased monocyte trans-
migration (34). Platelet CD62P is critical in initiating
platelet adhesion to circulatingmonocytes. This then leads
to monocyte activation and an increased integrin expres-
sion, including CD11b, that mediates monocyte firm ad-
hesion (34) andproduction of inflammatory cytokines and
chemokines by monocytes, including TNF-a and C-C
motif ligand 2 (35). These platelet–leukocyte aggregates
are also a source of proinflammatory mediators, such as
potent smoothmuscle contractantsLTC4 andLTD4 (36). In
the present study, we found that both atorvastatin and
pravastatin reduced circulating monocyte and platelet
activation as well as monocyte–platelet aggregates, an
action thatwas reversed after COX-2 inhibition (Fig. 6 and
Supplemental Fig. 3). These findings support the role of
RvTs in mediating the protective actions of these 2 statins
in regulating systemic inflammation and processes that
are associated with the development of CVD.
In rheumatoid arthritis, unabated leukocyte recruit-
ment and activation leads to a perpetuation of joint in-
flammation and joint destruction. Among the leukocytes
that are recruited to the joint, nonclassic monocytes were
recently found to be essential in initiating joint in-
flammation in murine arthritis (28), whereas neutrophils
play an important role in perpetuating joint damage via
release of proteinases and production of extracellular
traps (37). The inflammatory milieu found in the joint is
also thought to be responsible for the differentiation of
recruited monocytes to inflammatory macrophages that
amplify joint inflammation by producing inflammatory
mediators, including cytokines and chemokines, and ac-
tivating the adaptive immune system (38). Results from
the present study demonstrate that atorvastatin and
pravastatin also regulate joint leukocyte recruitment and
activation, reducing nonclassic monocyte, neutrophil,
and macrophage numbers as well as the expression of
activationmarkers. These actionsweremediated byRvTs,
as inhibiting their production reversed the protective ac-
tions of both statins and lead to an increase in joint in-
flammation (Figs. 5 and 6). Regulation of both systemic
and local leukocyte responses is also in line with the
biologic actions of RvTs. Indeed, these mediators po-
tently regulate human leukocyte responses at concen-
trations identified in plasma and tissues in the present
study (13). This is also in linewith the biologic actions of
other proresolving mediators that stereospecifically
regulate monocyte, macrophage, and neutrophil ac-
tivation (15–17, 29, 39, 40).
Taken together, these results establish the rank order
potencies of atorvastatin, pravastatin, and simvastatin at
regulating RvTs. Joint and systemic increases in these
proresolving mediators also correlated with the ability of
each of these statins to dampen various aspects of local
and systemic inflammation, including edema, leukocyte,
and platelet activation. Thus, these results establish a
novel mechanism of action for atorvastatin and prava-
statin in regulating inflammation in arthritis. In addition,
they also provide potential novel functional biomarkers
for measuring the efficacy of statins in controlling local
and vascular inflammation in patients with rheumatoid
arthritis.
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10. Mäki-Petäjä, K. M., Booth, A. D., Hall, F. C., Wallace, S. M., Brown, J.,
McEniery, C. M., and Wilkinson, I. B. (2007) Ezetimibe and
simvastatin reduce inflammation, disease activity, and aortic
stiffness and improve endothelial function in rheumatoid arthritis.
J. Am. Coll. Cardiol. 50, 852–858
11. Shirinsky, I. V., Zheltova, O. I., Solovyova, N. Y., Kozlov, V. A., and
Shirinsky, V. S. (2009) Changes in disease activity, cytokine
production, and proliferation of peripheral blood mononuclear
cells in patients with rheumatoid arthritis after simvastatin treatment.
Scand. J. Rheumatol. 38, 23–27
12. Spite, M., and Serhan, C. N. (2010) Novel lipid mediators promote
resolution of acute inflammation: impact of aspirin and statins. Circ.
Res. 107, 1170–1184
RvTs MEDIATE STATINS’ ACTIONS IN IA 3647
 Vol.31,  No.8 , pp:3636-3648, August, 2017The FASEB Journal. 161.23.96.77 to IP www.fasebj.orgDownloaded from 
13. Dalli, J., Chiang,N., and Serhan,C. N. (2015)Elucidation of novel 13-
series resolvins that increase with atorvastatin and clear infections.
Nat. Med. 21, 1071–1075
14. Primdahl,K.G.,Aursnes,M.,Walker,M.E.,Colas,R.A., Serhan,C.N.,
Dalli, J.,Hansen,T. V., andVik,A. (2016) Synthesis of 13(R)-Hydroxy-
7Z,10Z,13R,14E,16Z,19Zdocosapentaenoic acid (13R-HDPA) and its
biosynthetic conversion to the 13-series resolvins. J. Nat. Prod. 79,
2693–2702
15. El Kebir, D., Gjorstrup, P., and Filep, J. G. (2012) Resolvin E1
promotes phagocytosis-inducedneutrophil apoptosis and accelerates
resolution of pulmonary inflammation. Proc. Natl. Acad. Sci. USA 109,
14983–14988
16. Fredman, G., Hellmann, J., Proto, J. D., Kuriakose, G., Colas, R. A.,
Dorweiler, B., Connolly, E. S., Solomon, R., Jones, D. M., Heyer,
E. J., Spite, M., and Tabas, I. (2016) An imbalance between
specialized pro-resolving lipid mediators and pro-inflammatory
leukotrienes promotes instability of atherosclerotic plaques. Nat.
Commun. 7, 12859
17. Serhan, C. N. (2017) Treating inflammation and infection in the 21st
century: new hints from decoding resolution mediators and
mechanisms. FASEB J. 31, 1273–1288
18. Viola, J. R., Lemnitzer, P., Jansen, Y., Csaba, G., Winter, C., Neideck,
C., Silvestre-Roig,C.,Dittmar,G.,Döring, Y.,Drechsler,M.,Weber,C.,
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Supplemental Table 1: Joint LM-SPM profiles during inflammatory arthritis. 
DHA Bioactive 
Metabolome 







RvD1 375 233 1.4 ± 0.4 2.4 ± 0.6 1.7 ± 0.7 2.5 ± 0.9 
RvD2 375 141 1.0 ± 0.3 1.4 ± 0.4 1.1 ± 0.3 0.9 ± 0.5 
RvD3 375 147 0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 
RvD4 375 101 2.3 ± 0.4 1.4 ± 0.2 1.7 ± 0.3 1.2 ± 0.3 
RvD5 359 199 20.2 ± 5.9 27.3 ± 7.8 22.6 ± 6.9 16.6 ± 8.0 
RvD6 359 101 2.7 ± 0.7 2.7 ± 0.6 2.4 ± 0.5 2.0 ± 0.7 
17R-RvD1 375 233 1.2 ± 0.5 0.7 ± 0.3 1.0 ± 0.3 0.9 ± 0.3 
17R-RvD3 375 147 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.0 0.1 ± 0.0 









PD1 359 153 41.2 ± 17.5 59.1 ± 37.1 29.8 ± 9.3 39.2 ± 23.0 
10S,17S-diHDHA 359 153 420.7 ± 152.2 506.6 ± 151.0 412.7 ± 114.0 406.8 ± 203.1 
17R-PD1 359 153 34.3 ± 10.3 45.0 ± 11.9 43.1 ± 14.2 39.0 ± 21.5 









MaR1 359 221 7.1 ± 1.4 12.6 ± 3.5 9.9 ± 2.9 8.6 ± 4.0 
7S,14S-diHDHA  351 221 32.7 ± 0.6 7.1 ± 1.8 3.4 ± 1.3 2.1 ± 0.8 
n-3 DPA Bioactive 
Metabolome                             
RvT1 377 193 2.7 ± 0.4 4.5 ± 0.7 4.3 ± 0.6 2.6 ± 0.7 
RvT2 377 215 0.5 ± 0.1 0.8 ± 0.2 0.6 ± 0.2 0.3 ± 0.1 
RvT3 377 143 0.9 ± 0.3 1.1 ± 0.2 1.0 ± 0.2 1.3 ± 0.4 
RvT4 361 193 4.3 ± 0.6 5.8 ± 1.0 3.5 ± 0.6 3.0 ± 0.3 









RvD1n-3 DPA 377 143 1.4 ± 0.8 0.9 ± 0.3 0.9 ± 0.3 0.1 ± 0.1 
RvD2n-3 DPA 377 233 1.0 ± 0.6 0.6 ± 0.2 0.7 ± 0.3 0.7 ± 0.3 
RvD5n-3 DPA 361 199 2.6 ± 0.6 2.7 ± 1.1 2.5 ± 0.8 1.3 ± 0.5 









PD1n-3 DPA 361 155 0.3 ± 0.1 0.9 ± 0.4 0.5 ± 0.2 0.2 ± 0.1 









MaR1n-3 DPA 361 223 1.0 ± 0.3 1.2 ± 0.3 1.0 ± 0.3 0.5 ± 0.3 
EPA Bioactive 
Metabolome                             
RvE1 349 195 0.1 ± 0.1 0.3 ± 0.2 0.4 ± 0.2 
 
-   
RvE2 333 199 5.7 ± 3.5 3.6 ± 2.0 4.1 ± 2.6 5.9 ± 2.8 
RvE3 333 201 0.6 ± 0.3 0.7 ± 0.4 0.3 ± 0.1 0.7 ± 0.4 
AA Bioactive 
Metabolome                             
LXA4 351 217 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.1 ± 0.1 
LXB4 351 221 13.3 ± 7.3 31.3 ± 21.3 22.4 ± 16.0 
 
-   
5S,15S-diHETE 335 115 16.5 ± 3.1 44.1 ± 15.9 27.9 ± 6.1 15.3 ± 5.3 
15-epi-LXA4 351 217 25.4 ± 10.5 17.1 ± 4.6 17.7 ± 3.9 9.2 ± 2.1 
15-epi-LXB4 351 221 2.0 ± 0.6 0.8 ± 0.3 1.5 ± 0.5 0.6 ± 0.2 









LTB4 335 195 27.4 ± 5.7 24.1 ± 11.4 32.0 ± 10.2 26.8 ± 9.7 









PGD2 351 189 3618.4 ± 1160.3 3794.1 ± 863.0 3352.3 ± 730.4 4640.6 ± 1203.9 
PGE2 351 189 3225.0 ± 849.3 3592.0 ± 654.4 3156.0 ± 649.3 4059.9 ± 961.0 
PGF2α 353 193 1124.0 ± 433.0 1106.7 ± 275.6 690.1 ± 130.0 1452.1 ± 446.2 
TxB2 369 169 548.4 ± 145.5 725.5 ± 172.2 430.1 ± 89.7 643.6 ± 141.8 
 
Paws were collected from mice 8 days after K/BxN-induced arthritis and giving atorvastatin, pravastatin, simvastatin 
(0.2mg/Kg) or vehicle (DPBS containing 0.05% ethanol). Lipid mediators were quantified using multiple reaction 
monitoring of the parent ion (Q1) and characteristic daughter ion (Q3). Results are expressed as mean ± s.e.m.; n = 
9-10 mice per group, 3 independent experiments. - = below limits of detection; limits of detection ~0.1 pg. Values 
denoted in bold are P < 0.05 vs. vehicle .  
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Supplemental Table 2: Day 8 plasma LM-SPM during inflammatory arthritis. 
DHA Bioactive 
metabolome 







RvD1 375 233 6.9 ± 4.6 10.8 ± 7.8 11.5 ± 5.7 5.4 ± 1.1 
RvD2 375 141 7.7 ± 3.9 11.3 ± 8.9 13.7 ± 7.9 1.7 ± 0.8 
RvD3 375 147 0.4 ± 0.2 0.8 ± 0.5 0.6 ± 0.3 0.4 ± 0.1 
RvD4 375 101 15.7 ± 3.8 21.8 ± 11.5 20.7 ± 8.2 8.0 ± 2.5 
RvD5 359 199 11.4 ± 5.6 6.0 ± 1.9 8.3 ± 1.9 10.6 ± 3.9 
RvD6 359 101 6.4 ± 1.9 4.8 ± 1.4 4.0 ± 1.3 2.7 ± 0.7 
17R-RvD1 375 233 3.9 ± 1.1 3.1 ± 1.4 3.9 ± 1.8 1.7 ± 0.6 
17R-RvD3 375 147 0.3 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 0.4 ± 0.1 









PD1 359 153 4.9 ± 1.9 27.5 ± 15.8 24.2 ± 16.9 8.1 ± 3.1 
10S,17S-diHDHA 359 153 95.3 ± 41.1 111.5 ± 40.2 152.7 ± 37.5 225.5 ± 100.7 
17R-PD1 359 153 5.8 ± 2.2 6.9 ± 2.5 10.0 ± 3.5 10.3 ± 3.7 









MaR1 359 221 39.8 ± 14.7 49.5 ± 17.1 31.6 ± 11.1 15.8 ± 3.4 
7S,14S-diHDHA  351 221 10.8 ± 3.7 11.4 ± 3.8 11.1 ± 4.6 7.5 ± 4.4 
n-3 DPA Bioactive 





RvT1 377 193 3.8 ± 1.4 4.8 ± 1.5 8.4 ± 3.1 1.8 ± 0.9 
RvT2 377 215 2.3 ± 1.2 3.0 ± 1.3 1.4 ± 0.4 3.3 ± 1.9 
RvT3 377 143 3.6 ± 1.5 1.8 ± 0.7 3.0 ± 1.4 3.6 ± 2.0 
RvT4 361 193 3.2 ± 0.8 5.8 ± 2.9 3.3 ± 1.1 0.7 ± 0.4 









RvD1n-3 DPA 377 143 5.0 ± 1.8 2.9 ± 1.1 5.2 ± 2.6 0.8 ± 0.3 
RvD2n-3 DPA 377 233 9.0 ± 4.5 6.6 ± 4.4 11.0 ± 5.1 6.1 ± 3.9 
RvD5n-3 DPA 361 199 2.5 ± 1.2 1.8 ± 0.6 2.6 ± 1.0 1.0 ± 0.3 









PD1n-3 DPA 361 155 3.6 ± 1.6 3.1 ± 1.4 3.7 ± 1.7 0.7 ± 0.3 









MaR1n-3 DPA 361 223 5.4 ± 1.8 6.0 ± 2.1 3.0 ± 1.1 1.8 ± 1.0 
EPA Bioactive 





RvE1 349 195 1.4 ± 0.8 4.4 ± 2.1 1.2 ± 0.7 7.1 ± 3.2 
RvE2 333 199 2.8 ± 1.1 4.6 ± 1.5 2.5 ± 1.4 1.4 ± 0.5 
RvE3 333 201 5.3 ± 2.4 2.5 ± 0.6 1.3 ± 0.4 2.5 ± 1.2 
AA Bioactive 





LXA4 351 217 1.5 ± 1.0 3.2 ± 2.1 2.4 ± 2.0 0.1 ± 0.1 
LXB4 351 221 48.2 ± 31.8 57.0 ± 32.9 27.3 ± 18.1 35.6 ± 35.3 
5S,15S-diHETE 335 115 21.9 ± 7.9 41.2 ± 19.8 38.6 ± 9.9 16.4 ± 4.4 
15-epi-LXA4 351 217 115.6 ± 32.6 149.9 ± 59.5 132.5 ± 47.1 42.6 ± 16.8 
15-epi-LXB4 351 221 18.9 ± 9.9 7.8 ± 3.3 8.5 ± 4.1 5.9 ± 3.3 









LTB4 335 195 182.4 ± 112.1 78.9 ± 28.0 110.1 ± 24.5 137.9 ± 79.5 









PGD2 351 189 832.0 ± 655.2 218.2 ± 131.9 465.4 ± 187.1 405.9 ± 250.9 
PGE2 351 189 1741.3 ± 1461.5 564.1 ± 448.5 610.0 ± 388.9 1080.3 ± 938.4 
PGF2α 353 193 883.9 ± 779.8 224.2 ± 144.5 263.8 ± 124.1 476.2 ± 340.8 
TxB2 369 169 3017.3 ± 1975.5 1218.2 ± 408.1 1651.8 ± 721.0 3765.1 ± 1259.1 
 
Plasma was collected from mice giving atorvastatin, pravastatin, simvastatin (0.2mg/Kg) or vehicle (DPBS containing 
0.05% ethanol) 8 days after disease onset. Lipid mediators were identified in accordance with published criteria and 
quantified using multiple reaction monitoring of the parent ion (Q1) and characteristic daughter ion (Q3). Results are 
expressed as mean ± s.e.m.; n = 9-10 mice per group from 3 independent experiments. Values denoted in bold are  
P < 0.05 vs. vehicle.  
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Supplemental Table 3: Plasma lipid mediators 2 hours after statin administration. 
DHA Bioactive 







RvD1 375 233 0.5 ± 0.1 0.7 ± 0.3 0.5 ± 0.1 
RvD2 375 141 1.7 ± 0.6 1.3 ± 0.4 1.1 ± 0.6 
RvD3 375 147 0.2 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 
RvD4 375 101 2.3 ± 0.5 3.1 ± 0.8 2.5 ± 0.3 
RvD5 359 199 0.4 ± 0.1 0.5 ± 0.1 0.9 ± 0.6 
RvD6 359 101 0.3 ± 0.1 0.3 ± 0.0 0.4 ± 0.1 
17R-RvD1 375 233 0.5 ± 0.2 0.3 ± 0.0 0.6 ± 0.2 
17R-RvD3 375 147 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.0 
                    
PD1 359 153 0.6 ± 0.5 0.2 ± 0.1 0.3 ± 0.1 
10S,17S-diHDHA 359 153 29.8 ± 16.6 6.5 ± 1.4 5.7 ± 1.2 
17R-PD1 359 153 2.2 ± 1.1 1.2 ± 0.8 0.3 ± 0.1 
                    
MaR1 359 221 3.8 ± 0.9 5.9 ± 1.2 4.2 ± 1.2 
7S,14S-diHDHA  351 221 13.4 ± 3.4 29.4 ± 11.6 11.5 ± 3.3 
n-3 DPA Bioactive 
Metabolome                       
RvT1 377 193 0.2 ± 0.1 1.0 ± 0.2 0.9 ± 0.2 
RvT2 377 215 0.2 ± 0.1 0.7 ± 0.1 0.3 ± 0.1 
RvT3 377 143 0.1 ± 0.0 0.5 ± 0.2 0.2 ± 0.0 
RvT4 361 193 0.2 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 
                   
RvD1n-3 DPA 377 143 0.9 ± 0.3 3.2 ± 2.4 0.8 ± 0.3 
RvD2n-3 DPA 377 233 1.9 ± 0.4 2.5 ± 0.9 1.3 ± 0.3 
RvD5n-3 DPA 361 199 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.1 
                   
PD1n-3 DPA 361 155 0.3 ± 0.0 0.4 ± 0.1 0.4 ± 0.2 
                   
MaR1n-3 DPA 361 223 0.5 ± 0.1 0.6 ± 0.1 0.4 ± 0.1 
EPA Bioactive 
Metabolome                       
RvE1 349 195 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.0 
RvE2 333 199 0.7 ± 0.2 0.5 ± 0.2 1.0 ± 0.4 
RvE3 333 201 0.6 ± 0.1 1.0 ± 0.1 0.9 ± 0.1 
AA Bioactive 
Metabolome                       
LXA4 351 217 1.1 ± 0.4 0.9 ± 0.4 0.4 ± 0.2 
LXB4 351 221 0.7 ± 0.1 1.1 ± 0.5 1.0 ± 0.5 
5S,15S-diHETE 335 115 1.7 ± 0.4 0.8 ± 0.2 0.8 ± 0.4 
15-epi-LXA4 351 217 0.2 ± 0.1 0.5 ± 0.2 0.3 ± 0.1 
15-epi-LXB4 351 221   -    -    -   
                   
LTB4 335 195 6.7 ± 1.0 5.6 ± 1.9 4.6 ± 1.8 
                   
PGD2 351 189 21.4 ± 10.9 9.5 ± 1.9 11.6 ± 1.9 
PGE2 351 189 20.4 ± 4.8 11.1 ± 3.4 14.4 ± 3.3 
PGF2α 353 193 8.0 ± 0.6 8.3 ± 1.7 7.8 ± 1.0 
TxB2 369 169 46.3 ± 9.3 56.8 ± 11.9 36.4 ± 10.7 
 
Plasma was collected 2h after atorvastatin (0.2mg/Kg), pravastatin (0.2mg/Kg) or vehicle (DPBS containing 0.05% 
ethanol) administration on 7 day of inflammatory arthritis. Lipid mediators were identified in accordance with 
published criteria and quantified using multiple reaction monitoring of the parent ion (Q1) and characteristic daughter 
ion (Q3). Results are expressed as mean ± s.e.m.; n = 4 mice per group. - = below limits of detection; limits ~0.1 pg. 





















































































Supplemental Figure 1: Increased plasma RvTby atorvastatin and pravastatin during inflammatory 
arthritis. Serum-induced arthritis was initiated in mice and atorvastatin, pravastatin (0.2 mg/Kg each) or 
vehicle (DPBS containing 0.05% ethanol) was given on days 3, 5 and 7. Blood was collected 2 hours after 
statin administration on day 7 and RvT were identified and quantified using lipid mediator profiling. (A) 
Representative MRM chromatograms of identified RvTn-3 DPA. (B) MS/MS spectra employed in the 
identification of RvT1 (inset, diagnostic ions). (C) Quantification of total RvT, RvT1, RvT2, RvT3 and RvT4 
compared to vehicle. Results for A, B are representative of n=12 mice, for C are mean ± s.e.m.; n = 4 mice 
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Supplemental Figure 2: Pravastatin dose-dependently increased RvT in human neutrophil-
endothelial cell co-incubations. HUVEC (8.5 x 105 cells/cm2) were incubated with IL-1β (10 ng/mL) and 
TNF-α (10 ng/mL) for 16h. These were then incubated with the indicated concentrations of atorvastatin, 
pravastatin or vehicle (DPBS containing 0.05% ethanol) for 30 minutes, then neutrophils (4 x 106 cells/well) 
were added. Incubations were quenched after 1h with 2 volumes of ice cold methanol and RvT were 
identified and quantified using lipid mediator profiling. (A) Representative MRM chromatograms of 
identified RvT. (B) MS-MS spectrum employed for the identification of RvT4. (C) RvT1, RvT2, RvT3 and 
RvT4 regulation compared with vehicle-treated incubations. Results are mean of 4 healthy donors from 4 
independent experiments. * p < 0.05 and ** p < 0.01 vs. vehicle using two-way ANOVA with post hoc 
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Supplemental Figure 3: Celecoxib reve ses the protective actions of pravastatin on systemic and joint 
leukocytes. Serum-induced arthritis was initiated, ons days 3, 5 and 7 and mice were administered celecoxib 
(10 mg/Kg) or vehicle (DPBS containing 0.05% ethanol) and after 1 hour given pravastatin (0.2mg/Kg) or 
vehicle (DPBS containing 0.05% ethanol). Blood was collected on day 8 and leukocyte subsets and activation 
were identified using fluorescently labeled antibodies and flow cytometry. (A-C) Activation markers on 
circulating (A) non-classical monocytes, (B) neutrophils and (C) platelets. Results are presented as percentage 
decrease from vehicle. (D-F) Leukocytes recovered from the inflamed paws (see methods for details) on day 8. 
Trafficking and activation profile for (D) non-classical monocytes (E) neutrophils (F) monocyte-derived 
macrophages were assessed using flow cytometry. Results are mean ± s.e.m.; n = 9 for vehicle, 11 for 
pravastatin and 6 for celecoxib mice per group from 2 independent experiments. * p < 0.05 vs. vehicle using 
one-way ANOVA with post hoc Dunnett’s multiple comparisons test. 6	
